High-level results from the Phase III OBERON and TITANIA trials revealed that the first-in-class monoclonal antibody reduced the annual rate of moderate-to-severe COPD exacerbations compared with placebo
CSPC will receive an upfront $1.2 billion from AstraZeneca for access to eight programmes, AI molecular design capabilities, and the LiquidGel platform
SLE remains a life-threatening autoimmune disease, with patients facing an elevated risk of early mortality and long-term organ damage
Here's a development that aims to keep your blood pressure in check. Literally!
Patients on baxdrostat showed a significant reduction in systolic blood pressure (SBP) compared to placebo
The TULIP-SC trial investigated the efficacy and safety of subcutaneous Saphnelo
The medicine was well tolerated, with no unexpected safety issue
Baxdrostat demonstrated a statistically significant and clinically meaningful reduction of systolic blood pressure compared with placebo
The collaboration furthers AstraZeneca’s presence in China following the $2.5bn investment in Beijing
Breztri is an inhaled triple-combination therapy approved for the treatment of chronic obstructive pulmonary disease
Subscribe To Our Newsletter & Stay Updated
